# Nab-Paclitaxel Combined With Local Therapy in Relapsed SCLC

> **NCT07547332** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Pulmonary Hospital, Shanghai, China** · enrollment: 84 (estimated)

## Conditions studied

- Small Cell Lung Cancer
- Extensive Stage Small Cell Lung Cancer (ES-SCLC)

## Interventions

- **RADIATION:** Albumin-bound Paclitaxel Combined with Local Therapy
- **DRUG:** Albumin-Bound Paclitaxel /nab-Paclitaxel

## Key facts

- **NCT ID:** NCT07547332
- **Lead sponsor:** Shanghai Pulmonary Hospital, Shanghai, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-06
- **Primary completion:** 2028-01-01
- **Final completion:** 2030-12-31
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07547332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07547332, "Nab-Paclitaxel Combined With Local Therapy in Relapsed SCLC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07547332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*